Anaplastic Large Cell Lymphoma Completed Phase 1 Trials for Bortezomib (DB00188)

Also known as: Lymphomas, Anaplastic Large-Cell / Anaplastic large-cell lymphoma / Large cell (Ki-1+) lymphoma / Lymphoma, Large-Cell, Anaplastic / Anaplastic large cell lymphoma, CD30-positive

DBCOND0028602 (Anaplastic Large Cell Lymphoma)Completed1 IdentifierTitlePurposeDrugs
NCT00348985PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or LymphomasTreatment
NCT01129180Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell LymphomaTreatment